ReviewMetabolic brain disease2026
Revisiting cirrhosis-related parkinsonism: a comprehensive review.
Review in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cirrhosis-related Parkinsonism is a frequent but often overlooked neurological complication of chronic liver disease, primarily driven by manganese (Mn) accumulation in the basal ganglia resulting from portosystemic shunting. Clinically, it presents as an atypical Parkinsonian syndrome characterized by bilateral and symmetrical motor features, early postural instability, and poor responsiveness to dopaminergic therapy, which distinguishes it from idiopathic Parkinson's disease. The underlying pathophysiology involves a complex cascade of Mn-induced neuroinflammation, mitochondrial dysfunction, and 𝛂-synuclein misfolding, particularly affecting the globus pallidus. While T1-weighted MRI typically reveals characteristic bilateral hyperintensities in the globus pallidus, its low specificity remains a significant diagnostic challenge, as these findings can occur in asymptomatic cirrhotic patients. Orthotopic liver transplantation stands as the only definitive treatment, offering potential for reversal of neurological deficits by restoring hepatic detoxification. Alternative strategies include interventional radiological shunt obliteration and symptomatic pharmacological therapies, though evidence for the latter remains inconsistent. This review synthesizes current knowledge on the epidemiology, pathogenesis, and management of this neurohepatic syndrome, highlighting the urgent need for standardized diagnostic criteria and validated biomarkers to improve clinical recognition and patient outcomes.
Indexed as
Identifiers
42174344What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.